Search Results - "Guillermo Aldana"

Low dose thymoglobulin versus basiliximab in cytomegalovirus positive kidney transplant recipients: Effectiveness of preemptive cytomegalovirus modified strategy by Montero, Camilo, Yomayusa, Nancy, Torres, Rodolfo, Cortes, Jorge, Alvarez, Carlos, Gallo, Juan, Aldana, Guillermo, Acevedo, Andres, Rios, Maria, Echeverri, Johana, Yepes, Zuly, Silva, Adriana, Gayon, Diana, Perez, Jorge, Ibanez, Milciades

“…We performed a retrospective trial to determine asymptomatic CMV reactivation and CMV disease in kidney allograft recipients with positive CMV serostatus…”
Get full text

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial by Aranda, Enrique, Viéitez, Jose Maria, Gómez-España, Auxiliadora, Gil Calle, Silvia, Salud-Salvia, Antonieta, Graña, Begoña, Garcia-Alfonso, Pilar, Rivera, Fernando, Quintero-Aldana, Guillermo Alfonso, Reina-Zoilo, Juan José, González-Flores, Encarnación, Salgado Fernández, Mercedes, Guillén‑Ponce, Carmen, Garcia-Carbonero, Rocio, Safont, María José, La Casta Munoa, Adelaida, García-Paredes, Beatriz, López López, Rafael, Sastre, Javier, Díaz-Rubio, Eduardo

“…Purpose5-Fluorouracil/leucovorin, oxaliplatin, irinotecan (FOLFOXIRI) plus bevacizumab is more effective than doublets plus bevacizumab as first-line therapy…”
Get full text

Prognostic and predictive markers of response to treatment in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nab-paclitaxel: Results of a retrospective analysis by Montes, Ana Fernández, Villarroel, Paula González, Ayerbes, Manuel Valladares, Gómez, Juan De la Cámara, Aldana, Guillermo Quintero, Tuñas, Lidia Vázquez, Fernández, Mercedes Salgado, Fernández, Mónica Jorge

“…Recent studies support the use of gemcitabine and nab-paclitaxel in adults with locally advanced unresectable or metastatic pancreatic adenocarcinoma although…”
Get full text

Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study) by López, Rafael, Méndez, Carlos Méndez, Fernández, Mónica Jorge, Reinoso, Carlos Romero, Aldana, Guillermo Quintero, Fernández, Mercedes Salgado, DE LA Cámara Gómez, Juan, López, Margarita Reboredo, Vázquez, Manuel Ramos, Folgar, Sonia Candamio

“…To evaluate the efficacy and safety of erlotinib plus capecitabine for metastatic pancreatic cancer. This was a multicenter, uncontrolled, phase II trial…”
Get full text

Efecto de retardantes de crecimiento en la disminución del volcamiento de sorgo dulce forrajero by Flórez Gómez, Deisy Lorena, Osorio Guerrero, Karen Viviana, Rodríguez Yzquierdo, Gustavo Adolfo, Jaramillo Bonilla, Sair, Ortegón Herrera, Luis Ernesto, Gómez Delgado, Evelin, Brochero Aldana, Guillermo Alberto

“…Introducción. Las plantas de sorgo dulce forrajero (Sorghum bicolor L. Moench) se caracterizan por presentar un porte alto, sin embargo, este atributo, junto…”
Get full text

Selección de leguminosas forrajeras como abono verde para sistemas doble propósito en el caribe seco: Leguminosas by Brochero Aldana, Guillermo Alberto, Mojica Rodríguez, José E, Sierra Alarcón, Andrea Milena, Castro Rincón, Edwin, Cardona Iglesias, Juan Leonardo, Burbano Erazo, Esteban

“…Se evaluó la producción de biomasa, la calidad nutricional y grado de preferencia de 10 leguminosas forrajeras fijadoras de nitrógeno para determinar la…”
Get full text

Posterior hamstring harvest improves aesthetic satisfaction and decreases sensory complications as compared to the classic anterior approach in anterior cruciate ligament reconstruction surgery by García Hernández, Jesús Manuel, López-Vidriero Tejedor, Emilio, Castañeda González, Sofía, Yrayzoz Fuentes, Joaquín, Periáñez Moreno, Rafael, Saval Benítez, Jose María, Carrascal Aldana, Guillermo

“…Purpose The use of the posterior approach for harvesting hamstring grafts has recently become popular thanks to new all-inside techniques and retrograde…”
Get full text

Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers by Fernández Montes, Ana, Martínez Lago, Nieves, Covela Rúa, Marta, de la Cámara Gómez, Juan, González Villaroel, Paula, Méndez Méndez, José Carlos, Jorge Fernández, Mónica, Salgado Fernández, Mercedes, Reboredo López, Margarita, Quintero Aldana, Guillermo, Luz Pellón Augusto, María, Graña Suárez, Begoña, García Gómez, Jesús

“…Purpose The phase III VELOUR trial demonstrated efficacy with combined FOLFIRI‐aflibercept in patients with metastatic colorectal cancer previously treated…”
Get full text

Manejo del trauma penetrante de cuello en dos hospitales de Bogotá, Colombia by Maikel Adolfo Pacheco, Guillermo Eduardo Aldana, Álvaro Eduardo Granados, Luis Eduardo Martínez, Jimena Santacoloma, Rogers Leonardo Baquero, Margarita María Ramírez

“…Introducción. El manejo del trauma penetrante de cuello en pacientes estables, según la zona de Monson lesionada, orienta la solicitud de pruebas…”
Get full text

Incidencia de falla anastomótica en intestino delgado, colon y recto, Bogotá, Colombia by Maikel Adolfo Pacheco, Guillermo Eduardo Aldana, Luis Eduardo Martínez, Juan Carlos Forero, Carlos Andrés Gómez, Esteban Mauricio Coral, Héctor Guillermo Olaya

“…Introducción. La falla anastomótica es una de las princi- pales complicaciones de las cirugías gastrointestinales, que se presenta en 3,4 a 15 % de los…”
Get full text

Factores predictores perioperatorios de complicaciones de la colecistectomía por laparoscopia by Guillermo Eduardo Aldana, Luis Eduardo Martínez, Manuel Augusto Hosman, Diego Alejandro Ardila, Iván Fernando Mariño, Michael Ricardo Sagra, Luisa María Montoya

“…Introducción. Los factores de riesgo para la conversión a laparotomía y las complicaciones de la colecistectomía laparoscópica se han estudiado, pero no…”
Get full text

Neo-adjuvant treatment of infiltrating transitional-cell carcinoma of the bladder with paclitaxel and cisplatin: A phase II trial by SOUSA-ESCANDÓN, ALEJANDRO, VAZQUEZ, SERGIO, QUINTERO-ALDANA, GUILLERMO, PICALLO, JOSE A, NEIRA, JAVIER, GARCIA-NOVIO, FRANCISCO, MATEO, A, RICO, MANUEL, MEL, JOSE R

“…Background : A phase II multicentric trial of paclitaxel and cisplatin was conducted in previously untreated patients, with locally advanced transitional‐cell…”
Get full text

El síndrome de compresión biliar extrínseca benigna o síndrome de Mirizzi: experiencia de cinco años en el Hospital de San José by Carolina Rodríguez, Guillermo Aldana

“…Introducción: el síndrome de compresión biliar extrínseca, o síndrome de Mirizzi, descrito por Pablo Mirizzi en 1948, es una entidad quirúrgica con baja…”
Get full text

Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study by Feliu, Jaime, Jorge Fernández, Mónica, Macarulla, Teresa, Massuti, Bartomeu, Albero, Ana, González González, José Federico, Quintero-Aldana, Guillermo, Delgado-Mingorance, Juan Ignacio, Fernández Montes, Ana, García Piernavieja, Carmen, Valladares-Ayerbes, Manuel, López Muñoz, Ana María, Mondéjar Solís, Rebeca, Vicente, Pilar, Casado Gonzalez, Esther, González Cebrián, Irene, López-Vivanco, Guillermo

“…Purpose To evaluate the health-related quality of life (HRQoL), global health status (GHS), and deterioration-free survival of an elderly population (>…”
Get full text

Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: BIBABRAX study by Feliu Batlle, Jaime, Jorge Fernandez, Monica, Macarulla, Teresa, Massuti, Bartomeu, Albero, Ana, Gonzalez, Federico, Quintero Aldana, Guillermo Alfonso, Mingorance, J. Ignacio Delgado, Fernandez Montes, Ana, Garcia Piernavieja, Carmen, Valladares-Ayerbes, Manuel, García Girón, Carlos, Mondejar, Rebeca, Vicente, Pilar, Casado, Esther, Gonzalez Cebrian, Irene, Lopez-Vivanco, Guillermo

“…Abstract only 4615 Background: FOLFIRINOX and nab-paclitaxel plus gemcitabine (nab-P+G) are the standard of care in the first-line treatment of mPC patients…”
Get full text

Low dose thymoglobulin versus basiliximab in cytomegalovirus positive kidney transplant recipients: Effectiveness of preemptive cytomegalovirus modified strategy by Montero, Camilo, Yomayusa, Nancy, Torres, Rodolfo, Cortes, Jorge, Alvarez, Carlos, Gallo, Juan, Aldana, Guillermo, Acevedo, Andres, Rios, Maria, Echeverri, Johana, Yepes, Zuly, Silva, Adriana, Gayon, Diana, Perez, Jorge, Ibanez, Milciades

“…We performed a retrospective trial to determine asymptomatic CMV reactivation and CMV disease in kidney allograft recipients with positive CMV serostatus…”
Get full text

Randomized phase II study on the influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab (Bev) or cetuximab (Cet), as first line therapy of patients (pts) with RAS wild-type metastatic colorectal carcinoma (mCRC) and <3 baseline circulating tumor cells (bCTCs) by Aranda, Enrique, Garcia-Alfonso, Pilar, Vieitez, Jose María, Ortiz, Maria Jose, López-López, Carlos, Reina-Zoilo, Juan José, Salud Salvia, Antonieta, Quintero Aldana, Guillermo Alfonso, Robles, Luis, Safont, Maria Jose, La Casta Munoa, Adelaida, Alés, Inmaculada, Polo Marques, Eduardo, Gallego Plazas, Javier, García de Paredes, Beatriz, Lopez, Rafael, Mónica, Guillot, Valladares-Ayerbes, Manuel, Sastre, Javier, Díaz-Rubio, Eduardo

“…Abstract only 3549 Background: The outcome for mCRC has changed since the introduction of new chemotherapy schedules and targeted therapies, however new…”
Get full text

Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs) by Sastre, Javier, Vieitez, Jose María, Gomez-España, Maria Auxilidora, Gil Calle, Silvia, Salud Salvia, Antonieta, Suárez, Begoña Graña, Garcia-Alfonso, Pilar, Martinez de Castro, Eva, Quintero Aldana, Guillermo Alfonso, Reina-Zoilo, Juan José, González Flores, Encarnación, Fernández, Mercedes Salgado, Guillen, Carmen, Garcia-Carbonero, Rocio, Safont, Maria Jose, La Casta Munoa, Adelaida, García de Paredes, Beatriz, Lopez, Rafael, Aranda, Enrique, Díaz-Rubio, Eduardo

“…Abstract only 3507 Background: FOLFOXIRI+BEV has demonstrated a survival benefit compared with FOLFIRI plus BEV (TRIBE Lancet Oncol 2015) in first-line mCRC…”
Get full text

What is the role of the anti-angiogenic therapy in BRAF (V600E) mutant metastatic colorectal cancer patients in a real-world setting? by Martinez Lago, Nieves, Covela Rúa, Marta, Brozos Vazquez, Elena, Fernandez Montes, Ana Fernandez, De La Camara Gomez, Juan Cruz, Méndez Méndez, Carlos, Jorge Fernández, Mónica, Cousillas Castiñeira, Antia, Suárez, Begoña Graña, Quintero Aldana, Guillermo Alfonso, Candamio Folgar, Sonia, Salgado Fernandez, Mercedes, Pellon Augusto, Maria Luz, Gonzalez Villarroel, Paula, Gallardo Martin, Elena, Carmona Campos, Marta, Vazquez Rivera, Francisca, Grande Ventura, Carlos, Carral Maseda, Alberto, Reboredo Lopez, Margarita

“…Abstract only 620 Background: Activating B-type Raf kinase (BRAF) mutations, mostly missense V600E, occur in approximately 8% to 12% of patients with…”
Get full text

The prognostic value of systemic inflammatory factors in BRAF (V600E) mutant metastatic colorectal cancer (mCRC) by Martinez Lago, Nieves, Covela Rúa, Marta, Brozos Vazquez, Elena, Fernandez Montes, Ana Fernandez, de la Cámara Gómez, Juan Cruz, Méndez Méndez, Carlos, Jorge Fernández, Mónica, Cousillas Castiñeira, Antia, Suárez, Begoña Graña, Quintero Aldana, Guillermo Alfonso, Candamio Folgar, Sonia, Salgado Fernandez, Mercedes, Pellon Augusto, Maria Luz, Gonzalez Villarroel, Paula, Gallardo Martin, Elena, Carmona Campos, Marta, Vazquez Rivera, Francisca, Grande Ventura, Carlos, Carral Maseda, Alberto, Reboredo Lopez, Margarita

“…Abstract only 622 Background: Multiple studies have reported prognostic association of neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLT)…”
Get full text